【中新健康】中国血友病治疗模式迈向个体化预防新阶段
中新网上海4月17日电 (记者 陈静)在第XX个世界血友病日之际，中国血友病的诊疗策略迎来了重大转变。中国医药教育协会止血与血栓分会副主任委员、中国罕见病联盟血友病学组主任委员杨仁池教授于17日表示，中国血友病的治疗模式已逐步从传统的“按需治疗”模式，转向更先进、更有效的“个体化预防治疗”模式。
血友病，一种影响血液凝固的遗传性疾病，长期困扰着患者及其家庭。据杨仁池教授介绍，过去的治疗方式主要是在出血发生后进行紧急止血处理，但这种“按需治疗”方式往往无法有效预防出血事件，且可能增加患者关节损伤的风险。随着医学技术的进步和对血友病理解的深入，中国医疗界开始倡导个体化预防治疗，通过定期输注凝血因子，防止出血事件，改善患者生活质量。
这一转变标志着中国在血友病管理领域取得了显著进步，与国际先进治疗理念接轨。个体化预防治疗不仅可以减少出血频率，降低并发症，还有助于减轻患者的心理负担，促进其社会功能的恢复。杨仁池教授强调，这种转变需要医生、患者和家庭的共同参与，以及社会各方的大力支持，以确保患者能够获得及时、持续的治疗。
中国罕见病联盟在推动血友病诊疗模式改革中发挥了关键作用，通过搭建交流平台、提升公众认知、推动政策支持等方式，助力血友病患者享受到更科学、更人性化的医疗服务。未来，中国将继续探索血友病的综合管理策略，以期实现更佳的临床效果和社会效益。
英语如下：
News Title: “China Advances into the Era of Personalized Prophylaxis for Hemophilia Treatment”
Keywords: Hemophilia treatment, personalized prophylaxis, paradigm shift
News Content:
**[Xinhua News – Health]** China’s approach to treating hemophilia is entering a new era of personalized prophylaxis, marking a significant shift in its treatment paradigm.
SHANGHAI, April 17 (Xinhua) – On the XXth World Hemophilia Day, China’s strategies for diagnosing and treating the condition have undergone a major transformation. Professor Yang Renci, Deputy Director of the Hemostasis and Thrombosis Branch of the China Association for Medical Education and the Chairman of the Hemophilia Group of the China Rare Disease Alliance, announced on the 17th that the country’s treatment model for hemophilia is transitioning from the traditional “on-demand treatment” approach to a more advanced and effective “personalized prophylaxis” method.
Hemophilia, a genetic disorder that impairs blood clotting, has long posed challenges for patients and their families. According to Professor Yang, previous treatment primarily involved emergency hemostasis after bleeding episodes. However, this “on-demand treatment” often failed to effectively prevent bleeding events and could increase the risk of joint damage. With advancements in medical technology and a deeper understanding of hemophilia, the Chinese medical community is now advocating for personalized prophylaxis, which involves regular infusions of clotting factors to prevent bleeding, thereby improving patients’ quality of life.
This shift signifies a significant stride in China’s management of hemophilia, aligning with international best practices. Personalized prophylaxis not only reduces the frequency of bleeding and associated complications but also alleviates psychological burdens and facilitates the recovery of patients’ social functioning. Professor Yang underscores the importance of the involvement of doctors, patients, families, and the broader community to ensure timely and sustained treatment for patients.
The China Rare Disease Alliance has played a pivotal role in reforming hemophilia treatment models, facilitating communication platforms, raising public awareness, and advocating for policy support. This has helped hemophilia patients access more scientific and humanized healthcare services. Looking forward, China will continue to explore comprehensive management strategies for hemophilia, aiming to achieve better clinical outcomes and social benefits.
【来源】http://www.chinanews.com/life/2024/04-17/10200803.shtml
Views: 1